Follow-On Biologics Guidances Will Take A Broad Approach
This article was originally published in The Pink Sheet Daily
Executive Summary
The plan is a shift from FDA’s previous intention to issue “product-specific” guidances.
You may also be interested in...
Follow-On Biologics Bill From Rep. Waxman To Be Introduced This Year
Legislation would allow FDA to take a “case-by-case” approach to approving generic versions of BLAs.
Follow-On Biologics Bill From Rep. Waxman To Be Introduced This Year
Legislation would allow FDA to take a “case-by-case” approach to approving generic versions of BLAs.
EMEA Product-By-Product Biosimilar Guidelines To Continue With Alfa Interferon
Additional product-level annexes to European biosimilar guidelines will be created as needed, German regulatory official Weise says.